The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Targeting p53 mutant ovarian cancer: Phase I results of the WEE1 inhibitor MK-1775 with carboplatin plus paclitaxel in patients (pts) with platinum-sensitive, p53-mutant ovarian cancer (OC).
Irene Brana
No relevant relationships to disclose
Kathleen N. Moore
No relevant relationships to disclose
Ronnie Shapira-Frommer
No relevant relationships to disclose
Stephen Welch
Research Funding - Amgen; Merck; Roche
Ying-Ming Jou
Employment or Leadership Position - Merck
Stock Ownership - Merck
Michelle Marinucci
Employment or Leadership Position - Merck
Tomoko Freshwater
Employment or Leadership Position - Merck
Shelonitda Rose
Employment or Leadership Position - Merck
Stock Ownership - Merck
Amit M. Oza
No relevant relationships to disclose